Form D · Biotechnology
Aura Biosciences, Inc.
Cambridge, MA · CIK 0001501796
Offering snapshot reported Apr 6, 2021 · SEC filing
- Reported sold
- $80.5M Offering amount: $80.5M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 6, 2021 | Initial | $80,483,829 | No comparison | Not reported | SEC filing |
| Jul 9, 2020 | Initial | $10,000,016 | No comparison | 32 | SEC filing |
| Apr 12, 2019 | Initial | $20,000,000 | No comparison | 36 | SEC filing |
| Dec 13, 2018 | Amendment | $42,272,525 | $9,831,047vs Jan 3, 2018 | 42 | SEC filing |
| Jan 3, 2018 | Initial | $32,441,478 | No comparison | 42 | SEC filing |
| Nov 2, 2017 | Amendment | $11,537,655 | $9,725,489vs Sep 30, 2016 | 38 | SEC filing |
| Sep 30, 2016 | Initial | $1,812,166 | No comparison | 27 | SEC filing |
| Mar 5, 2015 | Initial | $21,017,623 | No comparison | 21 | SEC filing |
| Aug 14, 2014 | Initial | $4,000,000 | No comparison | 41 | SEC filing |
| Jan 8, 2014 | Initial | $1,335,000 | No comparison | 16 | SEC filing |
| Dec 26, 2012 | Initial | $3,226,728 | No comparison | 22 | SEC filing |
| Aug 26, 2011 | Initial | $2,925,000 | No comparison | 23 | SEC filing |
| Sep 21, 2010 | Initial | $1,425,000 | No comparison | 18 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-394732
Source: Form D, filed Apr 6, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jose' Baselga, Ph.D. | Director |
| Jose Baselga, Ph.D. | Director |
| Lawrence C. Best | Director |
| Casper Breum | Director |
| Mark Chin | Director |
| Elisabet De Los Pinos, Ph.D. | Director, Executive |
| Julie Feder | Executive |
| Peter B. Finn | Executive |
| Javier Garcia | Director |
| Salvador Garcia Atance | Director |
| Lewis Geffen | Executive |
| George Golumbeski, Ph.D. | Director |
| Pedro Granadillo | Director |
| Joel Jean Mairet, Ph.D. | Director |
| David Johnson | Director |
| Sebastian Julia | Director |
| Giovanni Mariggi, Ph.D. | Director |
| Edmundo Muniz, M.D., Ph.D. | Director |
| Art Pappas | Director |
| Raj Parekh, Ph.D. | Director |
| Dale Pfost, Ph.D. | Director |
| Israel Ruiz | Director |
| Christian Schetter | Director |
| Karan Takhar | Director |
| Henri Termeer | Director |
| Alan Walts | Director |
| Alan E. Walts, Ph.D. | Director |
| Peter Wirth | Director |
| Michael Wyzga | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
85 Bolton Street
Cambridge, MA, 02140
Cambridge, MA, 02140